DrugDashboards

Telmisartan and Amlodipine

telmisartan and amlodipine · TELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 10 mg/1 · Tablet · Oral · Mylan Pharmaceuticals Inc.

NDC 00378-1078-93 · 30 TABLET in 1 BOTTLE, PLASTIC · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $2.98 per unit over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$2.98per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D point of sale (median)$3.08per unitnegotiated price across 4,409 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.08per unit
middle half $1.84$4.59 · 4,409 plans · Apr 1, 2026
Est. net of rebates
≈ $3.08
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
80%of plans cover it
tier 1 · prior auth 0% · step therapy 0% · qty limit 85%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Dec 2014Sep 2026$2.98
37 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$89.33
#90 count
$268.00

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$59,292
452 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for telmisartan and amlodipine (oral solid) in the next 90 days

sole-source market · price up 6% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA202516
TE code
Approval date
Aug 26, 2014
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of telmisartan and amlodipine (Tablet)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals LimitedTELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 10 mg/1Aug 26, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 5 mg/1Aug 26, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 10 mg/1Aug 26, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 5 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 5 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 10 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 40 mg/1; AMLODIPINE BESYLATE 5 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 80 mg/1; AMLODIPINE BESYLATE 10 mg/1Aug 26, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 5 mg/1; AMLODIPINE BESYLATE 80 mg/1Jul 22, 2026Aug 19, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 5 mg/1; AMLODIPINE BESYLATE 40 mg/1Jul 22, 2026Aug 19, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 10 mg/1; AMLODIPINE BESYLATE 80 mg/1Jul 22, 2026Aug 19, 2026
Alembic Pharmaceuticals LimitedTELMISARTAN 10 mg/1; AMLODIPINE BESYLATE 40 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 10 mg/1; AMLODIPINE BESYLATE 40 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 10 mg/1; AMLODIPINE BESYLATE 80 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 5 mg/1; AMLODIPINE BESYLATE 40 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.TELMISARTAN 5 mg/1; AMLODIPINE BESYLATE 80 mg/1Jul 22, 2026Aug 19, 2026
Alembic Pharmaceuticals LimitedAMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 40 mg/1Jul 15, 2026Jul 15, 2026
Alembic Pharmaceuticals LimitedAMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 80 mg/1Jul 15, 2026Jul 15, 2026
Alembic Pharmaceuticals LimitedAMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 40 mg/1Jul 15, 2026Jul 15, 2026
Alembic Pharmaceuticals LimitedAMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 80 mg/1Jul 15, 2026Jul 15, 2026
Mylan Pharmaceuticals Inc.AMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 40 mg/1Jul 15, 2026Jul 15, 2026
Mylan Pharmaceuticals Inc.AMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 40 mg/1Jul 15, 2026Jul 15, 2026
Mylan Pharmaceuticals Inc.AMLODIPINE BESYLATE 10 mg/1; TELMISARTAN 80 mg/1Jul 15, 2026Jul 15, 2026
Mylan Pharmaceuticals Inc.AMLODIPINE BESYLATE 5 mg/1; TELMISARTAN 80 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Telmisartan and Amlodipine — NDC 00378-1078-93," retrieved September 3, 2026, https://drugdashboards.com/drug/00378107893.

Free to cite with attribution — see how the data is put together.